Peter Maimonis

734 total citations
19 papers, 599 citations indexed

About

Peter Maimonis is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, Peter Maimonis has authored 19 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Radiology, Nuclear Medicine and Imaging, 8 papers in Oncology and 8 papers in Immunology. Recurrent topics in Peter Maimonis's work include Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and HER2/EGFR in Cancer Research (4 papers). Peter Maimonis is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (10 papers), Glycosylation and Glycoproteins Research (6 papers) and HER2/EGFR in Cancer Research (4 papers). Peter Maimonis collaborates with scholars based in United States, Germany and Hong Kong. Peter Maimonis's co-authors include Shunji Ogata, Steven H. Itzkowitz, Tanja Fehm, Alexander Katalinic, Wolfram Jäger, Daniel F. Hayes, Donald Küfe, Carl O’Hara, Lucien Perey and Miyako Abe and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Peter Maimonis

19 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Maimonis United States	11	331	294	252	159	77	19	599
John B. Beard United States	7	302 0.9×	110 0.4×	121 0.5×	168 1.1×	63 0.8×	8	513
Robert Hinderer United States	13	497 1.5×	116 0.4×	125 0.5×	199 1.3×	50 0.6×	14	754
Sylvie M�nard Italy	7	227 0.7×	262 0.9×	193 0.8×	87 0.5×	74 1.0×	10	489
Edward W. Blank United States	13	406 1.2×	186 0.6×	392 1.6×	230 1.4×	62 0.8×	31	681
Marina Kiso Japan	4	410 1.2×	120 0.4×	123 0.5×	176 1.1×	53 0.7×	5	577
Rita Pellegrini Italy	12	266 0.8×	246 0.8×	184 0.7×	115 0.7×	77 1.0×	18	556
K Zinkewich-Péotti Canada	10	298 0.9×	157 0.5×	116 0.5×	42 0.3×	78 1.0×	15	502
LG Durrant United Kingdom	14	231 0.7×	161 0.5×	133 0.5×	217 1.4×	53 0.7×	26	497
Cheng‐Pang Hsu United States	9	396 1.2×	197 0.7×	99 0.4×	151 0.9×	59 0.8×	9	574
Margaret Beckwith United States	14	304 0.9×	296 1.0×	85 0.3×	391 2.5×	89 1.2×	27	801

Countries citing papers authored by Peter Maimonis

Since Specialization

Citations

This map shows the geographic impact of Peter Maimonis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Maimonis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Maimonis more than expected).

Fields of papers citing papers by Peter Maimonis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Maimonis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Maimonis. The network helps show where Peter Maimonis may publish in the future.

Co-authorship network of co-authors of Peter Maimonis

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Maimonis. A scholar is included among the top collaborators of Peter Maimonis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Maimonis. Peter Maimonis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Chan, Anissa, Xiaohong Qiu, Richard M. Walsh, et al.. (2016). Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation. PLoS ONE. 11(11). e0165909–e0165909. 37 indexed citations

2.

Merdek, Keith D., et al.. (2011). Abstract 4898: Circulating tumor cell capture on a microfluidic chip incorporating both affinity and size. Cancer Research. 71(8_Supplement). 4898–4898. 10 indexed citations

3.

Maimonis, Peter, et al.. (2010). Affinity and size capture of circulating tumor cells: A platform for increased sensitivity. Clinical Cancer Research. 16(19_Supplement). B5–B5. 1 indexed citations

4.

Fields, Jeremy Z., Zhenqiang Gao, Marcia Lewis, et al.. (2004). Immunoassay for wild-type protein in lymphocytes predicts germline mutations in patients at risk for hereditary colorectal cancer. Journal of Laboratory and Clinical Medicine. 143(1). 59–66. 1 indexed citations

5.

Harris, Lyndsay N., Vlayka Liotcheva, Gloria Broadwater, et al.. (2001). Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy. Journal of Clinical Oncology. 19(6). 1698–1706. 89 indexed citations

6.

Treon, Steven P., Peter Maimonis, Gloria Young, et al.. (2000). Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 96(9). 3147–3153. 16 indexed citations

7.

Treon, Steven P., Peter Maimonis, Gloria Young, et al.. (2000). Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma. Blood. 96(9). 3147–3153. 70 indexed citations

8.

Cheung, Tak Hong, et al.. (1999). Clinical Use of Serum c-erbB-2 in Patients with Ovarian Masses. Gynecologic and Obstetric Investigation. 48(2). 133–137. 12 indexed citations

9.

Taylor, John A., Erik T. Goluboff, Robert J. Krane, et al.. (1999). THE HUMAN CARCINOMA ANTIGEN. The Journal of Urology. 209–209. 4 indexed citations

10.

Fehm, Tanja, Peter Maimonis, Alexander Katalinic, & Wolfram Jäger. (1997). The Prognostic Significance of c-erbB-2 Serum Protein in Metastatic Breast Cancer. Oncology. 55(1). 33–38. 51 indexed citations

11.

Fehm, Tanja, et al.. (1997). Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Research and Treatment. 43(1). 87–95. 60 indexed citations

12.

Ogata, Shunji, Peter Maimonis, & Steven H. Itzkowitz. (1992). Mucins bearing the cancer-associated sialosyl-Tn antigen mediate inhibition of natural killer cell cytotoxicity.. PubMed. 52(17). 4741–6. 101 indexed citations

13.

Maimonis, Peter, et al.. (1992). A new radioimmunoassay detecting early stages of colon cancer: a comparison with CEA, AFP, and Ca 19-9.. PubMed. 9(5). 265–71. 18 indexed citations

14.

Perey, Lucien, Daniel F. Hayes, Peter Maimonis, et al.. (1992). Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen.. PubMed. 52(9). 2563–8. 89 indexed citations

15.

Maimonis, Peter, et al.. (1991). Lung cancer-associated protein: development and characterization of a new assay that detects a circulating lung cancer marker.. PubMed. 51(15). 3838–42. 3 indexed citations

16.

Maimonis, Peter, et al.. (1990). An analysis of immunocomplexes for the detection of the early stages of colon cancer. Cancer. 65(6). 1338–1344. 9 indexed citations

17.

Maimonis, Peter, Daniel F. Hayes, Carl O’Hara, & Donald Küfe. (1990). Detection and characterization of a high molecular weight human lung carcinoma-associated glycoprotein.. PubMed. 50(20). 6738–43. 6 indexed citations

18.

Suit, Herman D., Peter Maimonis, Howard B. Michaels, & Robert Sedlacek. (1981). Comparison of Hyperbaric Oxygen and Misonidazole in Fractionated Irradiation of Murine Tumors. Radiation Research. 87(2). 360–360. 21 indexed citations

19.

Suit, Herman D., Daniel E. Dosoretz, Peter Maimonis, & Robert Sedlacek. (1980). Anaesthesia and efficacy of hyperbaric oxygen in radiation therapy. British Journal of Radiology. 53(633). 920–920. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact